Milestone Pharmaceuticals Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2018 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Milestone Pharmaceuticals Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2018 to Q2 2025.
  • Milestone Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2025 was $1.31M, a 5.97% decline year-over-year.
  • Milestone Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2025 was $5.53M, a 27.7% decline year-over-year.
  • Milestone Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5.78M, a 39.4% decline from 2023.
  • Milestone Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2023 was $9.53M, a 5.37% increase from 2022.
  • Milestone Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2022 was $9.05M, a 24.3% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 $5.53M $1.31M -$83K -5.97% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 $5.62M $1.35M -$161K -10.6% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q4 2024 $5.78M $1.47M -$403K -21.5% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-13
Q3 2024 $6.18M $1.4M -$1.47M -51.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $7.65M $1.39M -$1.1M -44.2% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 $8.75M $1.51M -$781K -34.1% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-14
Q4 2023 $9.53M $1.88M -$266K -12.4% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-13
Q3 2023 $9.8M $2.87M +$492K +20.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $9.31M $2.49M +$81K +3.36% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $9.23M $2.29M +$179K +8.47% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $9.05M $2.14M +$168K +8.51% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 $8.88M $2.38M +$356K +17.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $8.52M $2.41M +$499K +26.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $8.03M $2.11M +$746K +54.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $7.28M $1.98M +$545K +38.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 $6.73M $2.02M +$681K +50.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $6.05M $1.91M +$721K +60.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $5.33M $1.37M +$387K +39.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $4.95M $1.43M +$1.08M +304% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 $3.87M $1.34M +$993K +284% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $2.88M $1.19M +$915K +332% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $1.96M $981K +$770K +365% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 $1.19M $354K +$11K +3.21% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-29
Q3 2019 $1.18M $350K +$265K +312% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 $915K $276K +$196K +245% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 $719K $211K +$86K +68.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 $633K $343K Oct 1, 2018 Dec 31, 2018 10-K/A 2020-10-23
Q3 2018 $85K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 $80K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 $125K Jan 1, 2018 Mar 31, 2018 10-Q 2019-06-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.